In:
PLOS ONE, Public Library of Science (PLoS), Vol. 18, No. 3 ( 2023-3-10), p. e0283024-
Abstract:
Early diagnosis of severe combined immunodeficiency (SCID), spinal muscular atrophy (SMA), and sickle cell disease (SCD) improves health outcomes by providing a specific treatment before the onset of symptoms. A high-throughput nucleic acid-based method in newborn screening (NBS) has been shown to be fast and cost-effective in the early detection of these diseases. Screening for SCD has been included in Germany’s NBS Program since Fall 2021 and typically requires high-throughput NBS laboratories to adopt analytical platforms that are demanding in terms of instrumentation and personnel. Thus, we developed a combined approach applying a multiplexed quantitative real-time PCR (qPCR) assay for simultaneous SCID, SMA, and 1 st -tier SCD screening, followed by a tandem mass spectrometry (MS/MS) assay for 2 nd -tier SCD screening. DNA is extracted from a 3.2-mm dried blood spot from which we simultaneously quantify T-cell receptor excision circles for SCID screening, identify the homozygous SMN1 exon 7 deletion for SMA screening, and determine the integrity of the DNA extraction through the quantification of a housekeeping gene. In our two-tier SCD screening strategy, our multiplex qPCR identifies samples carrying the HBB : c.20A 〉 T allele that is coding for sickle cell hemoglobin (HbS). Subsequently, the 2 nd tier MS/MS assay is used to distinguish heterozygous HbS/A carriers from samples of patients with homozygous or compound heterozygous SCD. Between July 2021 and March 2022, 96,015 samples were screened by applying the newly implemented assay. The screening revealed two positive SCID cases, while 14 newborns with SMA were detected. Concurrently, the qPCR assay registered HbS in 431 samples which were submitted to 2 nd -tier SCD screening, resulting in 17 HbS/S, five HbS/C, and two HbS/β thalassemia patients. The results of our quadruplex qPCR assay demonstrate a cost-effective and fast approach for a combined screening of three diseases that benefit from nucleic-acid based methods in high-throughput NBS laboratories.
Type of Medium:
Online Resource
ISSN:
1932-6203
DOI:
10.1371/journal.pone.0283024
DOI:
10.1371/journal.pone.0283024.g001
DOI:
10.1371/journal.pone.0283024.g002
DOI:
10.1371/journal.pone.0283024.t001
DOI:
10.1371/journal.pone.0283024.s001
DOI:
10.1371/journal.pone.0283024.s002
DOI:
10.1371/journal.pone.0283024.s003
DOI:
10.1371/journal.pone.0283024.s004
DOI:
10.1371/journal.pone.0283024.s005
DOI:
10.1371/journal.pone.0283024.s006
DOI:
10.1371/journal.pone.0283024.s007
DOI:
10.1371/journal.pone.0283024.r001
DOI:
10.1371/journal.pone.0283024.r002
DOI:
10.1371/journal.pone.0283024.r003
DOI:
10.1371/journal.pone.0283024.r004
Language:
English
Publisher:
Public Library of Science (PLoS)
Publication Date:
2023
detail.hit.zdb_id:
2267670-3
Permalink